Sanofi Shares Fall After Company Reports Second Cancer Case in Trial -- Market Talk

Dow Jones03-30

1039 GMT - Sanofi shares fall after the French pharmaceutical company reported a second case of a patient developing Kaposi's sarcoma, a type of cancer that affects the skin, in a late-stage study for experimental eczema treatment amlitelimab. "Kaposi's sarcoma occurs with other immunomodulators but in our view additional risk factors can be unfavorable if there are other treatment options that don't have those risks," analysts at UBS say in a note. Sanofi says amlitelimab continues to have potential to be a meaningful and convenient option for patients with atopic dermatitis, or eczema. The company reported the second Kaposi's sarcoma case at the annual meeting of the American Academy of Dermatology. It had previously disclosed a case when it released initial results from two amlitelimab phase 3 studies in January. Shares fall 2.15%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

March 30, 2026 06:40 ET (10:40 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623965319?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 18:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623965319","market":"us","top_or_hot":-1,"title":"Sanofi Shares Fall After Company Reports Second Cancer Case in Trial -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1039 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> shares fall after the French pharmaceutical company reported a second case of a patient developing Kaposi's sarcoma, a type of cancer that affects the skin, in a late-stage study for experimental eczema treatment amlitelimab. \"Kaposi's sarcoma occurs with other immunomodulators but in our view additional risk factors can be unfavorable if there are other treatment options that don't have those risks,\" analysts at UBS say in a note. <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> says amlitelimab continues to have potential to be a meaningful and convenient option for patients with atopic dermatitis, or eczema. The company reported the second Kaposi's sarcoma case at the annual meeting of the American Academy of Dermatology. It had previously disclosed a case when it released initial results from two amlitelimab phase 3 studies in January. Shares fall 2.15%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 30, 2026 06:40 ET (10:40 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Shares Fall After Company Reports Second Cancer Case in Trial -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Shares Fall After Company Reports Second Cancer Case in Trial -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-30 18:40</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1039 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> shares fall after the French pharmaceutical company reported a second case of a patient developing Kaposi's sarcoma, a type of cancer that affects the skin, in a late-stage study for experimental eczema treatment amlitelimab. \"Kaposi's sarcoma occurs with other immunomodulators but in our view additional risk factors can be unfavorable if there are other treatment options that don't have those risks,\" analysts at UBS say in a note. <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> says amlitelimab continues to have potential to be a meaningful and convenient option for patients with atopic dermatitis, or eczema. The company reported the second Kaposi's sarcoma case at the annual meeting of the American Academy of Dermatology. It had previously disclosed a case when it released initial results from two amlitelimab phase 3 studies in January. Shares fall 2.15%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 30, 2026 06:40 ET (10:40 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2623965319","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623965319","pubTimestamp":1774867200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1039 GMT - Sanofi shares fall after the French pharmaceutical company reported a second case of a patient developing Kaposi's sarcoma, a type of cancer that affects the skin, in a late-stage study for experimental eczema treatment amlitelimab. \"Kaposi's sarcoma occurs with other immunomodulators but in our view additional risk factors can be unfavorable if there are other treatment options that don't have those risks,\" analysts at UBS say in a note. Sanofi says amlitelimab continues to have potential to be a meaningful and convenient option for patients with atopic dermatitis, or eczema. The company reported the second Kaposi's sarcoma case at the annual meeting of the American Academy of Dermatology. It had previously disclosed a case when it released initial results from two amlitelimab phase 3 studies in January. Shares fall 2.15%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4588":"碎股","SNYNF":"Sanofi","BK4007":"制药","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","SNY":"赛诺菲安万特"},"translate_title":"赛诺菲报告第二例癌症病例正在试验后股价下跌——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNYNF":1.5,"SNY":0.9},"content_text":"1039 GMT - Sanofi shares fall after the French pharmaceutical company reported a second case of a patient developing Kaposi's sarcoma, a type of cancer that affects the skin, in a late-stage study for experimental eczema treatment amlitelimab. \"Kaposi's sarcoma occurs with other immunomodulators but in our view additional risk factors can be unfavorable if there are other treatment options that don't have those risks,\" analysts at UBS say in a note. Sanofi says amlitelimab continues to have potential to be a meaningful and convenient option for patients with atopic dermatitis, or eczema. The company reported the second Kaposi's sarcoma case at the annual meeting of the American Academy of Dermatology. It had previously disclosed a case when it released initial results from two amlitelimab phase 3 studies in January. Shares fall 2.15%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 30, 2026 06:40 ET (10:40 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623965319","isCrawlerRequest":true}